Over the past several years, orphan drugs have accounted for more than 40% of new drug approvals by the FDA. In this podcast, we showcase an article that explores whether they are producing the revenue gains pharma companies are seeking or if they are too niche?
Key topics: (see Chapter Markers)
- Inside new drug approvals and drug-development trends for orphan drugs
- Inside the market for orphan drugs
- Market outlook for orphan drugs
- Orphan-drug NMEs and market penetration
Sponsor: CordenPharma
